Resistance to imatinib (Gleevec) caused by LYN kinase

Data published in this weeks Journal of the National Cancer Institute shows that activation of LYN kinase is associated with resistance to imatinib (Gleevec) in patients with chronic myelogenous leukemia (CML)

Exelixis begin Phase II trial of multikinase inhibitor XL184 in Glioblastoma Multiforme

Exelixis are initiating a Phase II trial of XL184 for the treatment of Malignant Glioma

Exelixis begin Phase I trial of PI3K/mTOR inhibitor XL765 in Glioma

Exelixis are initiating a Phase I trial of XL765, in combination with Temozolomide, for the treatment of Malignant Glioma

Imatinib increases thrombolytic therapeutic window in stroke

Researchers from the University of Michigan and the Karolinska Institute have found that imatinib (Gleevec) extends the three-hour thrombolytic therapeutic window for ischemic stroke in a mouse model. The drug was found to reduce edema associated with ischemic stroke and improvethe response to tissue plasminogenactivator.